{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-011873","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2025-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.167029+00:00","generated_at":"2026-05-20T22:45:35.194375+00:00","sec_items":["7.01","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Dermata initiates XYNGARI drug product manufacturing; Phase 3 STAR-2 trial expected Q4 2025","bullets":["Manufacturing for XYNGARI drug product initiated for Phase 3 STAR-2 trial; trial start expected Q4 2025.","Topline data from STAR-2 expected H1 2027; patients can rollover into 9-month extension study.","NDA filing for XYNGARI anticipated in H1 2028 after extension study completion by end of Q4 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-011873","json":"https://secwatch.observer/filing/0001641172-25-011873.json","markdown":"https://secwatch.observer/filing/0001641172-25-011873.md","text":"https://secwatch.observer/filing/0001641172-25-011873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000164117225011873/0001641172-25-011873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000164117225011873/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T22:45:35.194375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}